Our proprietary Binder Selection Technology offers a transformative approach to small-molecule screening, capable of identifying specific binders from our extensive 400,000-compound library against even the most challenging targets. Unlike conventional methods, our technology enables direct screening of membrane proteins without solubilization, preserving their native structure throughout the process. This innovation allows us to target not only soluble proteins, but also a broad range of membrane proteins—including GPCRs, ion channels, and transporters—as well as target RNAs.
Key features:

• No membrane solubilization required – Screening is performed in a native-like environment without disrupting membrane proteins.
• Any protein target – Applicable to soluble proteins, membrane proteins, orphan receptors, and proteins with unknown biological functions.
• RNA target compatibility – Capable of screening binders to structured RNAs, expanding the target landscape beyond proteins.
• 400,000-compound library – Access to a large, diverse library allows efficient identification of novel, highly specific binders.

Using a single, unified platform, Binder Selection Technology streamlines the discovery of small-molecule binders with high specificity across a wide range of biological targets. This opens the door to first-in-class drug discovery in areas previously considered intractable.

Using our proprietary Binder Selection Technology, we have built an extensive Binder Collection—a database of specific small-molecule binders targeting a wide range of proteins, including:

• GPCRs
• SLC transporters
• Ion channels
• Regulatory proteins
• Scaffold proteins

This collection enables researchers to quickly initiate validation assays or functional studies using pre-identified binders, significantly shortening timelines from target selection to experimental evaluation.
The table below shows representative examples:

• 197 GPCR targets with confirmed binders
• 153 SLC transporters with validated binders

These collections continue to grow, supporting rapid and efficient exploration of diverse targets.
With our ready-to-use binder database, immediate follow-up studies are possible—accelerating your discovery process.

We offer a powerful target identification service that screens compounds of unknown mechanism against our library of 17,000 human proteins, including membrane proteins.
Using our proprietary platform:

• No immobilization of compounds or proteins is required.
• Membrane proteins are screened in their native-like states without solubilization.
• All proteins are overexpressed, allowing detection of binders even for low-abundance intracellular targets.

By performing binding assays directly against a wide protein panel, we can efficiently identify the target protein for your compound.
Our platform is also ideal for phenotypic screening follow-up, helping translate phenotypic hits into defined molecular targets—accelerating your drug discovery pipeline.Let us help reveal the targets behind your bioactive compounds.